Company intelligence / Profile preview

HaniPharm

Ownership: Private
Development stage: Other

Overview

Hanmi Pharmaceutical is a leading Korean R&D-centric biopharmaceutical company with a strong track record in developing innovative medicines. It has commercialized numerous drugs domestically and internationally—including Korea’s first salt-modified new drug for hypertension—and outlicensed technologies to major global pharma companies. Its portfolio spans prescription drugs for oncology and chronic diseases as well as OTC products. Notable achievements include the first FDA-approved novel biologic from Korea ("Rolvedon") and several fixed-dose combination therapies.

Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Roche (Ceftriaxone manufacturing technology)Novartis (micro-emulsion technology)Crystal Genomics

Beyond the preview

Go deeper on HaniPharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HaniPharm.

Explore the full profile